In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Idec buys Biogen for $6.84bn in stock

Executive Summary

In a merger of equals, Idec Pharmaceutical (cancer and autoimmune disease therapies) is buying Biogen (autoimmune and cancer therapeutics) for stock worth $6.84bn, which is about seven times Biogen's 2002 sales. The combined entity, Biogen Idec Inc., will be the third largest biotech.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies